RPL35AP32

Across TCGA pan-cancer cohorts, RPL35AP32 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of RPL35AP32’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where RPL35AP32 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL35AP32 is over-expressed in tumor, although a few such as BRCA and LUSC show the opposite, repressed pattern.

KIRC, HNSC, and BRCA are the cancer types where RPL35AP32 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL35AP32 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	All	+0.224	<.001	7	view →
HNSC	All	All	+0.216	.001	7	view →
BRCA	All	III,IV	−0.327	<.001	4	view →
LUSC	All	All	−0.278	.003	3	view →
CHOL	Male	All	+0.316	.010	2	view →
THCA	Female	All	−0.160	.006	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

RPL35AP32–KIRC

Open the KIRC breakdown →